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Code Topic
WPE Designing and conducting pharmacoeconomic studies that get used
WTG Issues in the development of treatment guidelines
WDM Practical issues in the use of pharmacoeconomic in decision-making 
Methodology Issues
WMM Methodology issues—modeling
WMS Methodology issues—statistical issues
WMD Methodology issues—data collection
WMQ Methodology issues—quality of life instruments
SESSION 1
WPE1
MODELING FOR POLICY-MAKERS THE 
EXPECTED BENEFITS OF PREVENTION
Leader S, Muhuri P
Pracon, Reston, VA, USA
WORKSHOP OBJECTIVE: This workshop will show how
to synthesize data from clinical trials and other sources to
derive the expected reductions in the incidence of adverse
events and estimate the potential cost savings if the vulnera-
ble population were provided with the effective interven-
tion. Participants will learn how available data can be used
to demonstrate to policy-makers the practical benefits of
targeting proven risk reduction methods to those at highest
risk. The beneficial effects of supplemental vitamins will be
used to illustrate the estimation method.
PARTICIPANTS WHO WOULD BENEFIT: Analysts,
drug and device manufacturers interested in leveraging
clinical trial results into favorable coverage and payment
decisions by policy-makers and third-party payers.
Scientific evidence about ways to reduce the risks of in-
jury, illness, and premature death often fails to be incor-
porated into private behavior and public policy because
researchers do not translate this information in a way
that spurs public action. Even when we know what
works, we often encounter resistance to adopting the in-
tervention due to fears that the costs will exceed the ben-
efits. Thus, adoption of legal requirements for seat belts,
airbags, and 55-mph speed limits occurred long after sci-
entists had established the effectiveness of these measures
in reducing automobile related injuries and fatalities. Par-
ticipants will be taught how to estimate the magnitude of
the preventable fraction of adverse events in a population
at risk, the estimated savings that would accrue, and the
cost-effectiveness of the targeted intervention. Using this
methodology, drug and device manufacturers can target
their messages to individuals most at risk and the third-
party payers who cover that vulnerable population.
WPE2
THE NUTS AND BOLTS OF CONDUCTING 
RANDOMIZED OUTCOMES TRIALS
Menzin J, Friedman M
Boston Health Economics, Inc., Billerica, MA, USA
WORKSHOP OBJECTIVE: To review and discuss the
practical issues and pitfalls in designing and conducting
Phase IV outcomes trials.
PARTICIPANTS WHO WOULD BENEFIT: Persons
who are responsible for contributing to the design and/or
implementation of outcomes trials would benefit from this
workshop, as would those who need to determine whether
such trials would be beneficial to their organizations.
There is an increasing awareness of the limitations of ex-
trapolating efficacy and safety data from Phase III ran-
domized clinical trials to typical practice settings. Phase IV
outcomes studies offer an opportunity to generate data on
the effectiveness of treatment and the costs of care in ac-
tual clinical practice, which is of increasing interest to
managed care organizations. However, there are numer-
ous challenges and pitfalls involved in carrying these stud-
ies out. In this workshop, these challenges will be reviewed
from the initial development of a protocol through the
publication of findings. Participants will learn about the
types of decisions that need to be made along the way.
Some of the issues that will be reviewed include how to se-
lect the appropriate comparators and outcome measures,
site selection and procedures for recruiting and randomiz-
ing subjects, and the preferred methods for collecting data
without excessive study intervention. Potential problems
in data analysis and the interpretation of findings also
will be considered. A variety of approaches for handling
the issues outlined above will be described using actual
examples from completed Phase IV outcomes studies.
